论文部分内容阅读
目的:探讨新辅助静脉化疗对中晚期宫颈癌患者的临床疗效及其可能作用机制。方法:收集于我院就诊或住院治疗的60例宫颈癌患者,根据治疗方案不同分为实验组和对照组,每组各30例。对照组患者采用放疗方案,实验组患者在对照组基础上应用新辅助静脉化疗方案,21 d为一疗程,共2个疗程。治疗期间密切注意患者的生命体征,并对出现的并发症进行及时治疗。治疗结束后,对患者的血清肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、患者副作用发生率以及临床疗效进行检测并比较。结果:与治疗前相比,两组患者治疗后的血清TNF-α、VEGF水平均显著下降(P<0.05);与对照组相比,实验组患者治疗后的血清TNF-α、VEGF水平及副作用发生率较低(P<0.05),临床治疗总有效率较高(P<0.05)。结论:新辅助静脉化疗能够显著提高中晚期宫颈癌患者的临床疗效并减少化疗相关的不良反应,这可能与其降低中晚期宫颈癌患者血清TNF-α、VEGF水平有关。
Objective: To investigate the clinical effect of neoadjuvant intravenous chemotherapy on patients with advanced cervical cancer and its possible mechanism. Methods: Sixty cervical cancer cases were collected from our hospital for treatment or hospitalization, and divided into experimental group and control group according to different treatment plans, with 30 cases in each group. Patients in the control group were treated with radiotherapy. Patients in the experimental group were treated with neoadjuvant intravenous chemotherapy on the basis of the control group, 21 days for a course of treatment for a total of 2 courses. Pay close attention to the vital signs of patients during treatment, and the timely treatment of complications occurred. After the treatment, the serum levels of tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), incidence of side effects and clinical efficacy of the patients were detected and compared. Results: Compared with the control group, the levels of serum TNF-α and VEGF in the two groups were significantly decreased after treatment (P <0.05). Compared with the control group, the levels of serum TNF- The incidence of side effects was lower (P <0.05), and the total effective rate of clinical treatment was higher (P <0.05). Conclusion: Neoadjuvant intravenous chemotherapy can significantly improve the clinical efficacy of patients with advanced cervical cancer and reduce chemotherapy-related adverse reactions, which may be related to its ability to reduce serum levels of TNF-α and VEGF in patients with advanced cervical cancer.